• 6

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 22 March 2001 (22.03.2001)

PCT

(10) International Publication Number WO 01/19844 A1

- (51) International Patent Classification⁷: C07H 21/04, C07K 14/435, 14/705, C12N 5/10, 15/00, 15/12, G01N 33/53
- [US/US]; Apt. 3D, 17 East 89th Street, New York, NY 10128 (US). LI, Yixin [US/US]; Apt. 9H, 430 East 63rd Street, New York, NY 10021 (US).
- (21) International Application Number: PCT/US00/24966
- (74) Agents: ZITRON, Anne, E. et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022-7513 (US).

- (22) International Filing Date:
 - 13 September 2000 (13.09.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

- (30) Priority Data:
 - 60/153,625

13 September 1999 (13.09.1999) U

- (71) Applicant (for all designated States except US): NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY [US/US]; 535 East 70th Street, New York, NY 10021 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CROW, Mary, K.


- 805 Third Avenue, New York, NY 10022-7513 (US).
- (81) Designated States (national): CA, JP, MG, US.
- (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.





(57) Abstract: This invention relates to alterations in the CD40 ligand (CD40L) promoter, and methods of identifying individuals at risk for a disease or condition in which an elevated expression of CD40L is a factor. Such diseases include autoimmune diseases such as Rheumatoid Arthritis (RA). Nucleic acids encoding for the altered CD40L promoter are provided. These nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing diseases or conditions in which an elevated expression of CD40L is a factor. The invention provides a diagnostic method in which a blood or tissue sample is taken from an individual at risk for RA, nucleic acid is extracted, and the CD40L promoter sequenced. The invention also provides a diagnostic method in which a blood or tissue sample containing cells expressing CD40L is taken from an individual at risk for RA, the transcriptional activity of the CD40L gene is measured, and compared to a control value. The invention further relates to screening for compounds that modulate the activity of an altered CD40L promoter. Such compounds can be used in treating or preventing diseases in which elevated expression of CD40L is a factor.